Although the current results clearly demonstrate that UBL3 modification regulates PD-L1 sorting to sEVs and that this process can be inhibited by statins in vitro, it remains to be determined whether these effects translate into enhanced anti-tumor immune responses in vivo. Here, UBL3 is linked to neoplasm.